Itinai.com light and shadow chase in a bright clinical trial 94e57646 2deb 4898 b35d 841dc91eb7a5 1
Itinai.com light and shadow chase in a bright clinical trial 94e57646 2deb 4898 b35d 841dc91eb7a5 1

Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial

Comparing Treatments for Macular Edema Secondary to Branch Retinal Vein Occlusion

Background

Macular edema (ME) is a common complication following branch retinal vein occlusion (BRVO) and is a major cause of visual impairment. This study aimed to compare the effectiveness and safety of three treatments for ME secondary to BRVO: intravitreal ranibizumab (IVR) monotherapy, dexamethasone implant (IDI) monotherapy, and a combination of IVR and IDI injections.

Methods

A total of 292 patients with unilateral ME secondary to BRVO were included in this study. They were randomly assigned to three groups and followed up for 12 months. Group 1 received IVR injections, group 2 received a combination of IVR and IDI injections, and group 3 received IDI injections. The study recorded and compared best corrected visual acuity (BCVA), central retinal thickness (CRT), complications, and frequency of injections between the three groups.

Results

Patients in all three groups showed improvement in BCVA and CRT reduction. The combination therapy (group 2) required fewer injections and had fewer complications compared to the other groups. However, group 3 had more frequent complications, particularly in patients who received repeated IDI injections.

Conclusion

All three treatment regimens were similarly effective in treating ME secondary to BRVO. The combination therapy showed an advantage in maintaining good effects with fewer reinjections and complications.

Trial Registration Information

The study was conducted in compliance with the principles of the Declaration of Helsinki and was approved by Xi’an Aier Ancient City Eye Hospital, Xi’an Aier Eye Hospital, and Xianyang Aier Eye Hospital ethics committees (2022SF-367).

Practical Solutions and Value

Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into an easily accessible knowledge base for clinicians. Additionally, our mobile apps support scheduling, monitoring treatments, and telemedicine, streamlining operations and improving patient outcomes. Learn more about how we can help at aidevmd.com.

AI-Powered Health Tools

Interactive AI Tools to Help You Understand Your Health

Solutions for Smart Healthcare

Clinical Research